Hereditary erythermalgia: A model to understand erythermalgia?;L'érythermalgie héréditaire: Un modèle pour comprendre l'érythermalgie?

Annales de Dermatologie et de Venereologie

Volumn 134, Issue 5, 2007, Pages 479-480

  Misery, L ^a  

^a CHU MORVAN   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; LIDOCAINE; MEXILETINE; N METHYL DEXTRO ASPARTIC ACID; NORADRENALIN; PHENYTOIN; PIZOTIFEN; PIZOTIFEN MALEATE; SEROTONIN; SODIUM CHANNEL; VENLAFAXINE;

ALPHA CHAIN; ARTICLE; CHROMOSOME 2Q; EDEMA; ERYTHEMA; ERYTHROMELALGIA; GENETIC DISORDER; GENETIC HETEROGENEITY; HUMAN; HYPERPOLARIZATION; HYPOGLYCEMIA; HYPOTENSION; HYPOTHERMIA; NEUROPATHY; NOCICEPTION; SENSORY NERVE CELL; VASODILATATION;

EID: 34249001029     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(07)89219-2     Document Type: Article

References (21)

1. Guillet MH, Schollhammer M, Le Noach E, Guillet G. Éythermalgie familiale traitée par pizotifène. Ann Pediatr 1996;43:599-603.
2. Drenth JPH, te Morsche RH, Guillet G, Taieb A, Kirby RL, Jansen JB. SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. J Invest Dermatol 2005;124:1333-8.
3. Legroux-Crespel E, Sassolas B, Guillet G, Kupfer I, Dupré D, Misery L. Traitement de l'érythermalgie familiale par l'association lidocaïne-méxilétine. Ann Dermatol Venereol 2003;130:429-33.
4. Drenth JPH, Finley WH, Breedveld GJ, Testers L, Michiels JJ, Guillet G, et al. The primary erythermalgia-susceptibility gene is located on chromosome 2q31-32. Am J Hum Genet 2001;68:1277-82.
5. Firmin D, Roguedas AM, Gréco M, Morvan C, Legoupil D, Fleuret C, et al. Treatment of familial erythromelalgia with venlafaxine. J Eur Acad Dermatol Venereol 2007 (in press).
6. Misery L, Gréco M, Fleuret C, Firmin D, Mocquard Y, Renault A, et al. Complications sévères de l'érythermalgie héréditaire. Ann Dermatol Venereol 2006;133:4S127.
7. 9A, encoding a sodium channel alpha subunit, in patients with primary erythermalgia. J Med Genet 2003;41:171-4.
8. Burns TM, Te Morsche RHM, Jansen JBMJ, Drenth JPH. Genetic heterogeneity and eclusion of a modifying locus at 2q in a family with autosomal dominant primary erythermalgia. Br J Dermatol 2005;153:174-7.
9. Waxman D, Dib-Hajj D. Erythermalgia: molecular basis for an inherited pain syndrome. Trends Mol Med 2005;11:555-62.
10. Orstavik K, Weidner C, Schmidt R, Schmelz M, Hilliges M, Jorum E, et al. Pathological C-fibres in patients with a chronic painful condition. Brain 2003;126:1-12.
11. Nassar MA, Stirling LC, Forlani G, Baker MD, Matthews EA, Dickenson AH, et al. Nociceptor-specific gene deletion reveals a major role for Nav1.7 (PN1) in acute and inflammatory pain. Proc Natl Acad Sci USA 2004;101:12706-11.
12. Waxman SG, Dib-Hajj D. Erythromelalgia: a hereditary pain syndrome enters the molecular era. Ann Neurol 2005;57:785-8.
13. Kuhnert SM, Phillips WJ, Davis MD. Lidocaine and mexiletine therapy for erythromelalgia. Arch Dermatol 1999;135:1447-9.
14. Nathan A, Rose JB, Guite JW, Hehir D, Milovich K. Primary erythromelalgia in a child responding to intravenous lidocaine and oral mexiletine treatment. Pediatrics 2005;115:e504-7.
15. Davis MD, Sandroni P. Lidocaine patch for pain of erythromelalgia: follow-up of 34 patients. Arch Dermatol 2005;141:1320-1.
16. Rush AM, Dib-Hajj D, Liu S, Cummins TR, Black JA, Waxman SG. A single sodium channel mutation produces hyper or hypoexcitability in different types of neurons. Proc Natl Acad Sci USA 2006;103:8245-50.
17. Davis MDP, Sandroni P, Rooke TW, Low PA. Erythromelalgia: vasculopathy, neuropathy or both? Arch Dermatol 2003;139:1337-43.
18. Kazemi R, Shooshtari SM, Nasab MR, Roghani RS, Haghighi FM. Sympathetic skin response (SSR) in erythromelalgia. Electromyogr Clin Neurophysiol 2003;43:165-8.
19. Davis MD, Genebriera J, Sandroni P, Fealey RD. Thermoregulatory sweat testing in patients with erythromelalgia. Arch Dermatol 2006;142:1583-8.
20. Moiin A, Yashar SS, Sanchez JE, Yashbar B. Treatment of erythromelalgia with a serotonin/noradrenaline reuptake inhibitor. Br J Dermatol 2002;146:336-7.
21. Sandroni P, Davis MD. Combination gel of 1% amitriptyline and 0.5% ketamine to treat refractory erythromelalgia pain: a new treatment option? Arch Dermatol 2006;142:283-6.